Ignite Creation Date:
2024-05-06 @ 2:56 PM
Last Modification Date:
2024-10-26 @ 1:40 PM
Study NCT ID:
NCT04471870
Status:
COMPLETED
Last Update Posted:
2022-03-09
First Post:
2020-07-06
Brief Title:
ARCANGELO itAlian pRospective Study on CANGrELOr
Sponsor:
Chiesi Farmaceutici SpA
Organization:
Chiesi Farmaceutici SpA
Study Overview
Official Title:
Multicentre Observational Prospective Cohort Study Including Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Who Receive Cangrelor iv Transitioning to Clopidogrel Prasugrel or Ticagrelor Per os
Status:
COMPLETED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ARCANGELO
Brief Summary:
The Sponsor implemented a post-authorisation safety study PASS category 3 focused in Acute Coronary Syndrome in order to collect information about the safety of cangrelor in the real clinical practice evaluating the safety of the transition to all the oral P2Y12 inhibitors cangrelor ticagrelor and prasugrel
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None